Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study

医学 肝细胞癌 队列 内科学 乙型肝炎病毒 胃肠病学 HBeAg 免疫学 肿瘤科 病毒 乙型肝炎表面抗原
作者
Qing-Jing Chen,Kongying Lin,Zhi-Wen Lin,Bing Zhang,Mingqiang Liu,Jianxi Zhang,Qi-Zhen Huang,Kecan Lin,Jinyu Zhang,Fuqun Wei,Peng-Hui You,You Song,Jiang Ya-bin,Hui Zhang,Zhiqing Cheng,Cong-Ren Wang,Yongyi Zeng
出处
期刊:International Immunopharmacology [Elsevier BV]
卷期号:125: 111098-111098 被引量:3
标识
DOI:10.1016/j.intimp.2023.111098
摘要

The efficacy and safety of tyrosine kinase inhibitors (TKIs) combined with anti-PD-1 antibodies (α-PD-1) in advanced hepatocellular carcinoma (HCC) with high hepatitis B virus (HBV) DNA levels (>500 IU/mL) remain unclear. We retrospectively assessed patients from seven medical institutions diagnosed with HBV-related HCC, undergoing treatment with TKIs and α-PD-1 in conjunction with antiviral therapies. Based on HBV-DNA levels, patients were categorized into either high (HHBV-DNA, >500 IU/mL) or low HBV-DNA (LHBV-DNA, ≤500 IU/mL) cohorts Propensity score matching (PSM) was used to minimize baseline imbalance between groups. 149 patients were included, with 66 patients exhibiting HBV-DNA > 500 IU/mL and 83 patients presenting HBV-DNA ≤ 500 IU/mL. Compared with the LHBV-DNA cohort, the HHBV-DNA cohort had a greater incidence of serum HBeAg positivity, tumor diameter ≥ 10 cm, and vascular invasion. Following PSM, 57 individuals were enrolled in each group. Oncological outcomes were comparable between HHBV-DNA and LHBV-DNA cohorts before and after PSM. Before PSM, the median PFS and OS were 6.1 months and 17.5 months in the HHBV-DNA cohort and 6.7 months and 19.3 months in the LHBV-DNA cohort (all P > 0.05). After PSM, the median PFS and OS were 6.0 months and 19.5 months in the HHBV-DNA cohort and 6.0 months and 17.1 months in the LHBV-DNA cohort, respectively (all P > 0.05). Safety profiles were equivalent across cohorts with no fatal incidents reported. Seven patients (4.7 %) had HBV reactivation. 1 (0.7 %) from HHBV-DNA and 6 (4.0 %) from LHBV-DNA (P = 0.134). Only one patient developed HBV-related hepatitis. The effectiveness and safety of TKIs plus α-PD-1 in advanced HCC with HBV-DNA > 500 IU/mL were not compromised in the context of concomitant antiviral therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
WJing发布了新的文献求助10
1秒前
量子星尘发布了新的文献求助10
1秒前
2秒前
butterfly完成签到,获得积分10
3秒前
丹青完成签到 ,获得积分10
3秒前
3秒前
老魏完成签到,获得积分10
4秒前
大个应助Ther采纳,获得10
4秒前
天才小能喵完成签到 ,获得积分0
4秒前
HuanChen完成签到,获得积分10
5秒前
苗广山完成签到,获得积分10
5秒前
stop here完成签到,获得积分10
5秒前
6秒前
hhh发布了新的文献求助10
6秒前
8秒前
semiaa完成签到,获得积分10
8秒前
汉堡包应助小猪采纳,获得10
11秒前
甜蜜的荟发布了新的文献求助10
11秒前
芜6完成签到,获得积分10
13秒前
berkelerey12138完成签到,获得积分10
13秒前
刘雪完成签到 ,获得积分10
14秒前
完美梨愁完成签到 ,获得积分10
14秒前
yyy完成签到,获得积分10
14秒前
李健的粉丝团团长应助zzzz采纳,获得10
15秒前
Dudidu完成签到,获得积分10
15秒前
一颗大树完成签到,获得积分10
16秒前
潇洒的浩然完成签到,获得积分10
17秒前
比比谁的速度快应助曾珍采纳,获得50
17秒前
19秒前
NiNi完成签到,获得积分10
20秒前
Ther完成签到,获得积分20
21秒前
傲娇白安完成签到,获得积分10
22秒前
22秒前
甜蜜的荟完成签到,获得积分20
23秒前
婷儿完成签到,获得积分10
23秒前
牛牛发布了新的文献求助10
23秒前
Hoper完成签到,获得积分10
23秒前
张曰淼完成签到,获得积分10
24秒前
共渡完成签到,获得积分10
26秒前
凉白开完成签到 ,获得积分10
27秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029